Identification

Name
Succinylcholine
Accession Number
DB00202  (APRD00159)
Type
Small Molecule
Groups
Approved
Description

A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. [PubChem]

Structure
Thumb
Synonyms
  • 2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
  • Dicholine succinate
  • Succinic acid, diester with choline
  • Succinocholine
  • Succinoylcholine
  • Succinylbischoline
  • Succinylcholine
  • Succinyldicholine
  • Suxamethonium
Product Ingredients
IngredientUNIICASInChI Key
Succinylcholine ChlorideI9L0DDD30I71-27-2YOEWQQVKRJEPAE-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnectineInjection, solution20 mg/mLIntramuscular; Intravenous; ParenteralSandoz1952-08-20Not applicableUs
AnectineInjection, solution20 mg/mLIntramuscular; Intravenous; ParenteralSandoz2017-06-22Not applicableUs
Anectine Flopack 500mgPowder, for solution500 mgIntravenousGlaxo Wellcome1959-12-311998-11-03Canada
Anectine Inj 20mg/mlLiquid20 mgIntravenousGlaxo Wellcome1952-12-312000-01-19Canada
QuelicinSolution100 mgIntravenousPfizer1976-12-31Not applicableCanada
QuelicinInjection, solution20 mg/mLIntramuscular; IntravenousRemedy Repack2017-11-272018-03-29Us
QuelicinInjection, solution20 mg/mLIntramuscular; IntravenousHospira, Inc.1953-05-01Not applicableUs
QuelicinSolution20 mgIntravenousPfizer1952-12-31Not applicableCanada
QuelicinInjection, solution20 mg/mLIntramuscular; IntravenousMedical Purchasing Solutions, Llc2014-03-31Not applicableUs
Quelicin Inj 20mg/ml USPSolution20 mgIntramuscular; IntravenousAbbott1985-12-312009-12-14Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Succinylcholine ChlorideInjection, solution20 mg/mLIntramuscular; IntravenousZydus Pharmaceuticals Usa, Inc.2018-05-10Not applicableUs
Succinylcholine ChlorideInjection, solution20 mg/mLIntramuscular; IntravenousCadila Pharnmaceuticals2018-05-10Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Succinylcholine ChlorideSuccinylcholine Chloride (20 mg/mL)Injection, solutionIntravenousCantrell Drug Company2015-03-122017-12-22Us
International/Other Brands
Scoline / Sucostrin
Categories
UNII
J2R869A8YF
CAS number
306-40-1
Weight
Average: 290.399
Monoisotopic: 290.220557458
Chemical Formula
C14H30N2O4
InChI Key
AXOIZCJOOAYSMI-UHFFFAOYSA-N
InChI
InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
IUPAC Name
trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium
SMILES
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C

Pharmacology

Indication

Used in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ECT)

Pharmacodynamics

Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is a depolarizing skeletal muscle relaxant. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Succinylcholine has no direct action on the uterus or other smooth muscle structures.

Mechanism of action

The mechanism of action of Succinylcholine involves what appears to be a "persistent" depolarization of the neuromuscular junction. This depolarization is caused by Succinylcholine mimicking the effect of acetylcholine but without being rapidly hydrolysed by acetylcholinesterase. This depolarization leads to desensitization.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-10
agonist
Human
AAlpha-7 nicotinic cholinergic receptor subunit
agonist
Human
AMuscarinic acetylcholine receptor M1
agonist
Human
UMuscarinic acetylcholine receptor M2
agonist
Human
UMuscarinic acetylcholine receptor M3
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

By pseudocholinesterase, to succinylmonocholine and choline.

Route of elimination

About 10% of the drug is excreted unchanged in the urine.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Voltage-dependent L-type calcium channel subunit alpha-1S---Not Availablec.3257G>A / c.520C>TADR InferredMalignant hyperthermia.Details
Ryanodine receptor 1---Not Availablec.103T>C / c.487C>T  … show all ADR InferredMalignant hyperthermia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Succinylcholine can be increased when it is combined with 1,10-Phenanthroline.Experimental
AcetyldigitoxinSuccinylcholine may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinSuccinylcholine may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AlfentanilSuccinylcholine may increase the bradycardic activities of Alfentanil.Approved, Illicit
AlphacetylmethadolSuccinylcholine may increase the bradycardic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineSuccinylcholine may increase the bradycardic activities of Alphaprodine.Illicit
AmbenoniumThe serum concentration of Succinylcholine can be increased when it is combined with Ambenonium.Approved
AmikacinThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
ApramycinApramycin may increase the respiratory depressant activities of Succinylcholine.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Succinylcholine.Investigational
BambuterolThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Bambuterol.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Succinylcholine.Experimental
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Succinylcholine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Succinylcholine.Approved
BezitramideSuccinylcholine may increase the bradycardic activities of Bezitramide.Experimental, Illicit, Withdrawn
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
Botulinum Toxin Type BSuccinylcholine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Succinylcholine.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
BuprenorphineSuccinylcholine may increase the bradycardic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Succinylcholine.Approved
ButorphanolSuccinylcholine may increase the bradycardic activities of Butorphanol.Approved, Illicit, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Succinylcholine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Succinylcholine.Approved, Investigational
CarfentanilSuccinylcholine may increase the bradycardic activities of Carfentanil.Illicit, Investigational, Vet Approved
CarvedilolThe risk or severity of hyperkalemia can be increased when Carvedilol is combined with Succinylcholine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Succinylcholine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Succinylcholine.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Succinylcholine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Succinylcholine.Approved, Investigational
ClindamycinThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Clindamycin.Approved, Vet Approved
CodeineThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
CoumaphosThe serum concentration of Succinylcholine can be increased when it is combined with Coumaphos.Vet Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Succinylcholine.Approved
CyclophosphamideThe serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinSuccinylcholine may increase the arrhythmogenic activities of Cymarin.Experimental
DecamethoniumThe serum concentration of Succinylcholine can be increased when it is combined with Decamethonium.Approved
DemecariumThe serum concentration of Succinylcholine can be increased when it is combined with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Succinylcholine.Approved
DeslanosideSuccinylcholine may increase the arrhythmogenic activities of Deslanoside.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Succinylcholine.Approved
DextromoramideSuccinylcholine may increase the bradycardic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneSuccinylcholine may increase the bradycardic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineSuccinylcholine may increase the bradycardic activities of Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Succinylcholine.Experimental
DichlorvosThe serum concentration of Succinylcholine can be increased when it is combined with Dichlorvos.Vet Approved
DigitoxinSuccinylcholine may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinSuccinylcholine may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Succinylcholine may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineSuccinylcholine may increase the bradycardic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineSuccinylcholine may increase the bradycardic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineSuccinylcholine may increase the bradycardic activities of Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Succinylcholine.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Succinylcholine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Succinylcholine.Approved, Investigational
DiphenoxylateSuccinylcholine may increase the bradycardic activities of Diphenoxylate.Approved, Illicit
DipivefrinThe serum concentration of Succinylcholine can be increased when it is combined with Dipivefrin.Approved
DistigmineThe serum concentration of Succinylcholine can be increased when it is combined with Distigmine.Experimental
DonepezilThe serum concentration of Succinylcholine can be increased when it is combined with Donepezil.Approved
DotarizineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Dotarizine.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.Approved, Vet Approved
DPDPESuccinylcholine may increase the bradycardic activities of DPDPE.Experimental
EchothiophateThe serum concentration of Succinylcholine can be increased when it is combined with Echothiophate.Approved
EdrophoniumThe serum concentration of Succinylcholine can be increased when it is combined with Edrophonium.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Succinylcholine.Approved, Investigational
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
EthanolSuccinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Succinylcholine.Approved
EthylmorphineSuccinylcholine may increase the bradycardic activities of Ethylmorphine.Approved, Illicit
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Succinylcholine.Approved
EtorphineSuccinylcholine may increase the bradycardic activities of Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe serum concentration of Succinylcholine can be increased when it is combined with Fenthion.Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Succinylcholine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluoxetine.Approved, Vet Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Succinylcholine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Succinylcholine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Succinylcholine.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Succinylcholine.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Succinylcholine.Approved, Investigational
GalantamineThe serum concentration of Succinylcholine can be increased when it is combined with Galantamine.Approved
Gallamine TriethiodideThe serum concentration of Succinylcholine can be increased when it is combined with Gallamine Triethiodide.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Succinylcholine.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Succinylcholine.Experimental
Ginkgo bilobaThe serum concentration of Succinylcholine can be increased when it is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GitoformateSuccinylcholine may increase the arrhythmogenic activities of Gitoformate.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Succinylcholine.Approved, Investigational
HeroinSuccinylcholine may increase the bradycardic activities of Heroin.Approved, Illicit, Investigational
Huperzine AThe serum concentration of Succinylcholine can be increased when it is combined with Huperzine A.Approved, Investigational
HydrocodoneSuccinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
HydromorphoneSuccinylcholine may increase the bradycardic activities of Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Succinylcholine.Vet Approved
IpidacrineThe serum concentration of Succinylcholine can be increased when it is combined with Ipidacrine.Experimental
IsepamicinIsepamicin may increase the respiratory depressant activities of Succinylcholine.Experimental
IsoflurophateThe serum concentration of Succinylcholine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
KanamycinKanamycin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational, Vet Approved
KetobemidoneSuccinylcholine may increase the bradycardic activities of Ketobemidone.Approved, Investigational
LabetalolThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Succinylcholine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Succinylcholine.Approved, Investigational
Lanatoside CSuccinylcholine may increase the arrhythmogenic activities of Lanatoside C.Experimental
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Succinylcholine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Succinylcholine.Approved
Levomethadyl AcetateSuccinylcholine may increase the bradycardic activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolSuccinylcholine may increase the bradycardic activities of Levorphanol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Succinylcholine.Experimental
LofentanilSuccinylcholine may increase the bradycardic activities of Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Succinylcholine.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Lorpiprazole.Approved
LosartanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Succinylcholine.Approved
Magnesium carbonateThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Succinylcholine.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Succinylcholine.Approved
Magnesium sulfateThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium Trisilicate.Approved
MalathionThe serum concentration of Succinylcholine can be increased when it is combined with Malathion.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Succinylcholine.Approved
MefloquineThe serum concentration of Succinylcholine can be increased when it is combined with Mefloquine.Approved, Investigational
MemantineThe serum concentration of Succinylcholine can be increased when it is combined with Memantine.Approved, Investigational
MeptazinolSuccinylcholine may increase the bradycardic activities of Meptazinol.Experimental
MethadoneSuccinylcholine may increase the bradycardic activities of Methadone.Approved
Methadyl AcetateSuccinylcholine may increase the bradycardic activities of Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe serum concentration of Succinylcholine can be increased when it is combined with Methanesulfonyl Fluoride.Investigational
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Succinylcholine.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinSuccinylcholine may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
MetoprololThe risk or severity of hyperkalemia can be increased when Metoprolol is combined with Succinylcholine.Approved, Investigational
MicronomicinMicronomicin may increase the respiratory depressant activities of Succinylcholine.Experimental
MinaprineThe serum concentration of Succinylcholine can be increased when it is combined with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
MorphineSuccinylcholine may increase the bradycardic activities of Morphine.Approved, Investigational
NalbuphineSuccinylcholine may increase the bradycardic activities of Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Succinylcholine.Experimental
NeomycinThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Neomycin.Approved, Vet Approved
NeostigmineThe serum concentration of Succinylcholine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
NicomorphineSuccinylcholine may increase the bradycardic activities of Nicomorphine.Experimental
NormethadoneSuccinylcholine may increase the bradycardic activities of Normethadone.Approved, Illicit
OleandrinSuccinylcholine may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Succinylcholine.Approved
OpiumSuccinylcholine may increase the bradycardic activities of Opium.Approved, Illicit
OuabainSuccinylcholine may increase the arrhythmogenic activities of Ouabain.Approved
OxycodoneThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational, Vet Approved
ParaoxonThe serum concentration of Succinylcholine can be increased when it is combined with Paraoxon.Experimental
ParomomycinThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Succinylcholine.Experimental
PentazocineSuccinylcholine may increase the bradycardic activities of Pentazocine.Approved, Vet Approved
PeruvosideSuccinylcholine may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineSuccinylcholine may increase the bradycardic activities of Pethidine.Approved
PhenazocineSuccinylcholine may increase the bradycardic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the neuromuscular blocking activities of Succinylcholine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Succinylcholine.Approved, Investigational
PhenoperidineSuccinylcholine may increase the bradycardic activities of Phenoperidine.Experimental
PhysostigmineThe serum concentration of Succinylcholine can be increased when it is combined with Physostigmine.Approved, Investigational
PiretanidePiretanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
PiritramideSuccinylcholine may increase the bradycardic activities of Piritramide.Approved, Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Succinylcholine.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Succinylcholine.Approved, Withdrawn
PramipexoleSuccinylcholine may increase the sedative activities of Pramipexole.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Succinylcholine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Succinylcholine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Succinylcholine.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Propafenone is combined with Succinylcholine.Approved
PropranololThe risk or severity of hyperkalemia can be increased when Propranolol is combined with Succinylcholine.Approved, Investigational
ProscillaridinSuccinylcholine may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Succinylcholine.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe serum concentration of Succinylcholine can be increased when it is combined with Pyridostigmine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Succinylcholine.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Succinylcholine.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Succinylcholine.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Succinylcholine.Approved
RemifentanilSuccinylcholine may increase the bradycardic activities of Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
RivastigmineThe serum concentration of Succinylcholine can be increased when it is combined with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Rizatriptan.Approved
RopiniroleSuccinylcholine may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Succinylcholine.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Succinylcholine.Investigational
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Succinylcholine.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Succinylcholine.Approved, Vet Approved
SufentanilSuccinylcholine may increase the bradycardic activities of Sufentanil.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Sumatriptan.Approved, Investigational
TacrineThe serum concentration of Succinylcholine can be increased when it is combined with Tacrine.Investigational, Withdrawn
TapentadolSuccinylcholine may increase the bradycardic activities of Tapentadol.Approved
TetracyclineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Succinylcholine.Investigational
TilidineSuccinylcholine may increase the bradycardic activities of Tilidine.Experimental
TobramycinTobramycin may increase the respiratory depressant activities of Succinylcholine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Succinylcholine.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
TramadolThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Tramadol.Approved, Investigational
TrichlorfonThe serum concentration of Succinylcholine can be increased when it is combined with Trichlorfon.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Succinylcholine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Succinylcholine.Approved
TubocurarineThe serum concentration of Succinylcholine can be increased when it is combined with Tubocurarine.Approved
TyrothricinThe serum concentration of Succinylcholine can be increased when it is combined with Tyrothricin.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Succinylcholine.Approved, Investigational
VancomycinThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Succinylcholine.Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Succinylcholine.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Zolmitriptan.Approved, Investigational
ZolpidemSuccinylcholine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Succinylcholine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Walter Raml, Gunther Eichberger, "Process for the preparation of succinylcholine halides." U.S. Patent US5206420, issued April 27, 1993.

US5206420
General References
  1. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. [PubMed:16571968]
External Links
Human Metabolome Database
HMDB0014347
KEGG Compound
C07546
PubChem Compound
5314
PubChem Substance
46506023
ChemSpider
5123
BindingDB
50061568
ChEBI
45652
ChEMBL
CHEMBL703
Therapeutic Targets Database
DAP001132
PharmGKB
PA451522
IUPHAR
4004
Guide to Pharmacology
GtP Drug Page
HET
SCK
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Succinylcholine
ATC Codes
M03AB01 — Suxamethonium
AHFS Codes
  • 12:20.20 — Neuromuscular Blocking Agents
PDB Entries
2ha2 / 2ha6
MSDS
Download (75.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentIntubation Conditions1
3CompletedTreatmentNeuromuscular Blockade1
3CompletedTreatmentAdjunct to general anesthesia therapy1
3RecruitingTreatmentStrokes1
4CompletedOtherDepolarizing Muscle Relaxants / Smooth muscle relaxation prior to radiological procedures1
4CompletedPreventionIntubation, Endotracheal1
4CompletedPreventionNeuromuscular Blockade / Postoperative Complications1
4CompletedTreatmentAnaesthesia therapy1
4CompletedTreatmentCaesarean Sections / Pregnancy1
4CompletedTreatmentDepression1
4CompletedTreatmentIntubation, Endotracheal1
4CompletedTreatmentIntubations1
4TerminatedTreatmentAnaesthesia therapy1
4Unknown StatusTreatmentCesarean Section1
4WithdrawnNot AvailableNeuromuscular Blockade1
Not AvailableActive Not RecruitingPreventionLaparoscopic Appendectomy1
Not AvailableCompletedNot AvailableNeuromuscular Blockade1
Not AvailableCompletedBasic ScienceDepression1
Not AvailableCompletedTreatmentElectroconvulsive Therapy / Neuromuscular Blockade1
Not AvailableCompletedTreatmentFasciculations / Intubating Conditions / Patients Satisfaction / Postoperative Myalgia / Throat Pain1
Not AvailableCompletedTreatmentIntubating Conditions / Performance With Respiratory Exercise Device / Postoperative Myalgia1
Not AvailableCompletedTreatmentPain1
Not AvailableRecruitingOtherAtelectasis / Complication of Ventilation Therapy / Tumor of Lung Parenchyma1
Not AvailableRecruitingTreatmentAnaesthesia therapy / General Surgery / Pain1
Not AvailableSuspendedTreatmentIntubating Conditions / Patients Satisfaction / Postoperative Myalgia1

Pharmacoeconomics

Manufacturers
  • Sandoz canada inc
  • Hospira inc
  • International medication systems ltd
  • Organon usa inc
  • Apothecon inc div bristol myers squibb
Packagers
  • Hospira Inc.
  • Pharmedium
  • Sandoz
  • Strides Arcolab Limited
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous; Parenteral20 mg/mL
Powder, for solutionIntravenous500 mg
LiquidIntravenous20 mg
Injection, solutionIntramuscular; Intravenous20 mg/mL
SolutionIntravenous100 mg
SolutionIntramuscular; Intravenous20 mg
Injection, solutionIntravenous20 mg/mL
SolutionIntravenous20 mg
Prices
Unit descriptionCostUnit
Succinylcholine-ns 140 mg/7 ml2.08USD ml
Quelicin 100 mg/ml vial1.2USD ml
Quelicin 20 mg/ml vial0.22USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000757 mg/mLALOGPS
logP-2.5ALOGPS
logP-8.4ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-6.8ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity100.94 m3·mol-1ChemAxon
Polarizability33.15 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9962
Blood Brain Barrier+0.7717
Caco-2 permeable+0.5871
P-glycoprotein substrateSubstrate0.5916
P-glycoprotein inhibitor INon-inhibitor0.9036
P-glycoprotein inhibitor IINon-inhibitor0.8503
Renal organic cation transporterNon-inhibitor0.7974
CYP450 2C9 substrateNon-substrate0.8434
CYP450 2D6 substrateNon-substrate0.8173
CYP450 3A4 substrateNon-substrate0.5158
CYP450 1A2 substrateNon-inhibitor0.936
CYP450 2C9 inhibitorNon-inhibitor0.9381
CYP450 2D6 inhibitorNon-inhibitor0.9278
CYP450 2C19 inhibitorNon-inhibitor0.9142
CYP450 3A4 inhibitorNon-inhibitor0.9281
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9831
Ames testNon AMES toxic0.8556
CarcinogenicityCarcinogens 0.5298
BiodegradationReady biodegradable0.7156
Rat acute toxicity2.3010 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9012
hERG inhibition (predictor II)Non-inhibitor0.8418
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acyl cholines. These are acylated derivatives of choline. Choline or 2-Hydroxy-N,N,N-trimethylethanaminium is a quaternary ammonium salt with the chemical formula (CH3)3N+(CH2)2OH.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Quaternary ammonium salts
Direct Parent
Acyl cholines
Alternative Parents
Fatty acid esters / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Amines
show 1 more
Substituents
Acyl choline / Fatty acid ester / Dicarboxylic acid or derivatives / Fatty acyl / Tetraalkylammonium salt / Carboxylic acid ester / Carboxylic acid derivative / Organic oxygen compound / Amine / Organooxygen compound
show 7 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
quaternary ammonium ion (CHEBI:45652)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Receptor binding
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an i...
Gene Name
CHRNA10
Uniprot ID
Q9GZZ6
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-10
Molecular Weight
49704.295 Da
References
  1. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. [PubMed:16571968]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Not Available
Specific Function
Not Available
Gene Name
CHRNA7
Uniprot ID
Q693P7
Uniprot Name
Alpha-7 nicotinic cholinergic receptor subunit
Molecular Weight
2987.635 Da
References
  1. Rogers KR, Fernando JC, Thompson RG, Valdes JJ, Eldefrawi ME: Detection of nicotinic receptor ligands with a light addressable potentiometric sensor. Anal Biochem. 1992 Apr;202(1):111-6. [PubMed:1621972]
  2. Fiacchino F, Ariano C, Gemma M, Cerrato D: Abnormal responses to succinylcholine and pancuronium in a patient with hemiparesis. Ital J Neurol Sci. 1990 Oct;11(5):497-9. [PubMed:2272786]
  3. Marshall CG, Ogden DC, Colquhoun D: The actions of suxamethonium (succinyldicholine) as an agonist and channel blocker at the nicotinic receptor of frog muscle. J Physiol. 1990 Sep;428:155-74. [PubMed:2133043]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fisher DM: Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm. 1999 Jun 1;56(11 Suppl 1):S4-9. [PubMed:10437710]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. [PubMed:9523819]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. [PubMed:9523819]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Ostergaard D, Engbaek J, Viby-Mogensen J: Adverse reactions and interactions of the neuromuscular blocking drugs. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):351-68. [PubMed:2682131]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:37